Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
search
Join
FREE
This site is intended for healthcare professionals
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Congress Hub
Toolkit
Paediatric Growth Calculator
DVT Risk Calculator
Due Date Calculator
Collaborate
About
EQOH
Careers
Contact Us
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
EMJ GOLD
CME
Join
FREE
Edition
European
US
Rheumatology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
The first and only approved dual inhibitor of IL-17A and IL-17F1-6
February 2026
BIMZELX® Demonstrated Deep and Sustained Efficacy to 3 Years Across Multiple Disease Domains of PsA and the Full axSpA Spectrum…
Read more
1
Mins
29 Jul 2019
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis
Fractalkine (CX3CL1, designated as FKN hereafter) is the sole member of the CX3C chemokine family which leads to dual actions, chemotaxis, and cell…
2
Mins
29 Jul 2019
Comparative Effectiveness Research in Observational Settings: Evaluating Two New Methods to Analyse Response Rates
Observational studies are being used more frequently to compare drug effectiveness. Authors typically report the proportion of patients…
9
Mins
29 Jul 2019
Considering the Patient Perspective: Challenges Facing Women with Axial Spondyloarthritis and Psoriatic Arthritis
Although gender is defined by psychological and social differences between men and women, and sex is defined by biological parameters based on genetics…
6
Mins
29 Jul 2019
EULAR 2019: Meet the Editorial Board
EULAR is much bigger than other congresses and meetings I usually attend, which are mostly at a national level. The science on offer is very broad…
2
Mins
29 Jul 2019
Circulating T Cell Clones in Preclinical Phases of Rheumatoid Arthritis
The aetiopathogenesis of rheumatoid arthritis (RA) is only partially understood, but is believed to result from a multi-step process, whereby…
5
Mins
29 Jul 2019
EULAR 2019 Interview: Meet the Organisers
Each year, the EULAR congress continues to grow larger and larger. Ensuring an exciting and fulfilling programme is an enormous undertaking…
11
Mins
29 Jul 2019
Metacognition in Rheumatoid Arthritis: Thinking About Our Thinking in Rheumatoid Arthritis Management
Since the 1990s, outcomes for patients with RA have steadily improved over time, with the treatment target for patients evolving from symptomatic relief…
1
Mins
29 Jul 2019
Comparison of PAXgene and Tempus Whole Blood RNA Collection and Isolation Systems for the Quantification of Type I Interferon-Stimulated Gene Expression
Type I IFN have important roles in many paediatric and adult rheumatic diseases and are a new therapeutic target for which several anti-IFN treatments…
Loading posts...
« Previous
1
…
58
59
60
61
62
…
83
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View